Advertisement

Synthetic Peptide Vaccines: The Quest to Develop Peptide Vaccines for Influenza, HIV and Alzheimer's Disease

  • Elisabetta Bianchi
  • Paolo Ingallinella
  • Marco Finotto
  • Joseph Joyce
  • Xiaoping Liang
  • Michael D. Miller
  • Gene G. Kinney
  • Gennaro Ciliberto
  • John W. Shiver
  • Antonello Pessi
Part of the Advances in Experimental Medicine and Biology book series (volume 611)

Introduction

The idea that the perfect vaccine would be of total synthetic making, composed only of chemically unambiguous material, dates back to the early ′80s [1,2]. However, despite considerable advances in both our understanding of the triggers of a protective immune response, and our ability to assemble increasingly complex macromolecular structures, no such vaccine has yet been approved for human use. Indeed, the initial enthusiasm has later been substituted by the prevailing belief that synthetic peptide vaccines are not possible.

In our laboratories we have been working towards this goal for a number of years, and we will highlight here some of our efforts to develop synthetic peptide vaccines for Alzheimer's disease (AD), HIV virus, and influenza virus. Our vaccines are aimed at eliciting a protective antibody response, and are based on chemically synthesized peptides corresponding to key protective B-cell epitopes, either used as such or conjugated to a protein carrier. The...

Keywords

Neisseria Meningitidis Phage Antibody Library Synthetic Peptide Vaccine Expose Surface Loop Viral Membrane Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Meloen, R.H., Langeveld, J.P.M., Schaaper, W.M.M., and Slootstra, J.W., Biologicals 29:233–236 (2001).CrossRefGoogle Scholar
  2. 2.
    Zauner, W., Lingnau, K., Mattner, F., von Gabain, A:, and Buschle, M., Biol. Chem. 382:581–595 (2001).Google Scholar
  3. 3.
    Chorev, M., and Goodman, M., Acc. Chem. Res. 26:266–273 (1993).CrossRefGoogle Scholar
  4. 4.
    Apostolopoulos, V., and Lazoura., E., Expert Rev. Vaccines 3:151–162 (2004).CrossRefGoogle Scholar
  5. 5.
    Morimoto, A., Irie, K., Murakami, K., Masuda, Y., Ohigashi, H., Nagao, M., et al., J. Biol. Chem. 279:52781–52788 (2004).CrossRefGoogle Scholar
  6. 6.
    Urbanc, B., Cruz, L., Yun, S., Buldyrev, S.V., Bitan, G., Teplow, D.B., and Stanley, H.E., Proc. Natl. Acad. Sci. U.S.A. 101:17345–17350 (2004).CrossRefGoogle Scholar
  7. 7.
    Burton, D.R., Stanfield, R.L., and Wilson, I.A., Proc. Natl. Acad. Sci. U.S.A. 102:149437#x2013; 14948 (2005).CrossRefGoogle Scholar
  8. 8.
    Miller, M.D., Geleziunas, R., Bianchi, E. Lennard, S., Hrin, R., Zhang, H., et al., Proc. Natl. Acad. Sci. U.S.A., 102:14759–14764 (2005).CrossRefGoogle Scholar
  9. 9.
    Luftig, M., Mattu, M., Di Giovine, P., Geleziunas, R., Hrin, R., Barbato, G., et al., Nature Struct. Mol. Biol., 13: 740–747 (2006).CrossRefGoogle Scholar
  10. 10.
    Bianchi, E., Finotto, M., Ingallinella, P., Hrin, R., Carella, A. V., Hou, X.. S., et al., Proc. Natl. Acad. Sci. U.S.A., 102:12903–12908 (2005).CrossRefGoogle Scholar
  11. 11.
    Webby, R. J., and Webster, R.G., Science 302:15197#x2013;1522 (2003).CrossRefGoogle Scholar
  12. 12.
    Fan, J., Liang, X., Horton, M.S., Perry, H.C., Citron, M.P., Heidecker, G.J., et al., Vaccine 22:2993–3003 (2004).CrossRefGoogle Scholar
  13. 13.
    Kemble, G., and Greenberg, H., Vaccine 21:1789–1795 (2003).CrossRefGoogle Scholar
  14. 14.
    Steinhauer, D. A., Virology 258:1–20 (1999).CrossRefGoogle Scholar
  15. 15.
    Bianchi, E., Liang, X., Ingallinella, P., Finotto, M., Chastain, M., Fan, J., et al., J. Virol. 79: 7380–7388 (2005).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Elisabetta Bianchi
    • 1
  • Paolo Ingallinella
    • 1
  • Marco Finotto
    • 1
  • Joseph Joyce
    • 2
  • Xiaoping Liang
    • 2
  • Michael D. Miller
    • 3
  • Gene G. Kinney
    • 4
  • Gennaro Ciliberto
    • 1
  • John W. Shiver
    • 2
  • Antonello Pessi
    • 1
  1. 1.IRBM-MRL Peptide Centre of ExcellencePomezia (Rome)Italy
  2. 2.Departments of Vaccine and Biologics ResearchMerck Research Laboratories, Sumneytown PikeWest PointUSA
  3. 3.Antiviral ResearchMerck Research Laboratories, Sumneytown PikeWest PointUSA
  4. 4.Alzheimer's ResearchMerck Research Laboratories, Sumneytown PikeWest PointUSA

Personalised recommendations